Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Privia Health (PRVA) EBITDA (2020 - 2026)

Privia Health has reported EBITDA over the past 6 years, most recently at $11.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 108.86% year-over-year to $11.4 million; the TTM value through Dec 2025 reached $35.0 million, up 93.38%, while the annual FY2025 figure was $35.0 million, 93.38% up from the prior year.
  • EBITDA for Q4 2025 was $11.4 million at Privia Health, down from $14.6 million in the prior quarter.
  • Over five years, EBITDA peaked at $14.6 million in Q3 2025 and troughed at -$192.9 million in Q2 2021.
  • A 5-year average of -$8.0 million and a median of $4.5 million in 2024 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: crashed 3017.54% in 2021 and later skyrocketed 387.56% in 2025.
  • Year by year, EBITDA stood at -$19.1 million in 2021, then skyrocketed by 113.33% to $2.5 million in 2022, then tumbled by 32.49% to $1.7 million in 2023, then skyrocketed by 219.11% to $5.5 million in 2024, then skyrocketed by 108.86% to $11.4 million in 2025.
  • Business Quant data shows EBITDA for PRVA at $11.4 million in Q4 2025, $14.6 million in Q3 2025, and $3.5 million in Q2 2025.